Clinical Trials Showcase
Monday 7 November
- Overall survival benefit of radium-223 chloride (Alpharadin™) in the treatment of patients with symptomatic bone metastases in castrationresistant cancer (CRPC): A phase III randomised trial (ALSYMPCA)
- Comparing BRAF inhibitor vemurafenib with dacarbazine V600EBRAF-mutated melanoma: A Phase III randomised, open-label, multicentre trial (BRIM3)
- Optimal sequencing of adjuvant chemotherapy (CT) and radiotherapy (RT) forwomen with early breast cancer (EBC): Results of the SECRAB trial. Presented on behalf of the SECRAB Steering Committee
- Alemtuzumab in combination with methylprednisolone is a highly effective regimen for patients with chronic lymphocytic leukaemia and deletion of TP53: Final results of the National Cancer Research Institute (NCRI) CLL206 Trial